-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, in the case of adjuvant treatment of melanoma, there are several treatment options to choose from.
In this trial, patients with stage IIIB-C or IV melanoma after surgical resection received nivolumab (3 mg/kg·2 weeks, n=452) or ipilimumab (10 mg/kg·3 weeks) , After 4 consecutive times, change to once every 12 weeks, n=453) treatment until the full year or disease recurrence, intolerable toxicity or withdrawal from the test
Patients in the nivolumab group received a median of 24 doses of nivolumab (range 1-26), and patients in the ipilimumab group received a median of 4 doses of ipilimumab (1-7)
Most treatment interruptions in the nivolumab group were due to disease recurrence (121/177), and most treatment interruptions in the ipilimumab group were due to drug toxicity (208/331) .
The occurrence of TRAE at different levels and time periods
The occurrence of TRAE at different levels and time periodsIn the nivolumab group, from the first dose to the last dose of nivolumab within 100 days, the incidence of TRAE for all grades was 67.
The incidence of all levels of TRAE was 67.
Relapse-free survival of patients with or without TRAE
Relapse-free survival of patients with or without TRAEWhether using landmark analysis, or analysis by the Cox model in the treatment arm, or by comparison with ipilimumab group, it was found no evidence of a correlation between the occurrence of TRAE RFS
No evidence of a correlation between the occurrence of TRAE and RFS was found.
The safety analysis results of nivolumab adjuvant therapy for melanoma are consistent with previous reports.
Original source:
Mandala Mario,Larkin James,Ascierto Paolo Antonio et al.
Adjuvant nivolumab for stage III / IV melanoma : evaluation of safety outcomes and association with recurrence-free survival
in this message
